Alba Rodríguez

DARATUMUMAB FOR THE TREATMENT OF MULTIPLE MYELOMA IN PATIENTS WITH HIGH-RISK CYTOGENETIC FACTORS

The authors of this review and meta-analysis of phase III trials evaluated the use of daratumumab for the treatment of newly diagnosed and relapsed/refractory multiple myeloma. While the individual trials did not demonstrate a statistically significant survival benefit, the meta-analysis did showed improvement in both progression-free and overall survival with daratumumab for both standard-risk and […]

DARATUMUMAB FOR THE TREATMENT OF MULTIPLE MYELOMA IN PATIENTS WITH HIGH-RISK CYTOGENETIC FACTORS Read More »

EFFICACY OF MAINTENANCE OLAPARIB FOR PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER WITH A BRCA MUTATION

News / Alba Rodríguez

Olaparib, a poly(ADP-ribose) polymerase (PARP) inhibitor, has demonstrated efficacy in several tumor types, including advanced ovarian cancer, breast, prostate, and pancreatic cancers. Olaparib is approved in the United States, the European Union, and other countries as maintenance treatment for women with germline or somatic BRCA-mutated advanced OC who are in response to first-line platinum-based chemotherapy

EFFICACY OF MAINTENANCE OLAPARIB FOR PATIENTS WITH NEWLY DIAGNOSED ADVANCED OVARIAN CANCER WITH A BRCA MUTATION Read More »

IMPLICATIONS OF TP53 ALLELIC STATE FOR GENOME STABILITY, CLINICAL PRESENTATION AND OUTCOMES IN MYELODYSPLASTIC SYNDROMES

News / Alba Rodríguez

Tumor protein p53 (TP53) is the most frequently mutated gene in cancer. In patients with myelodysplastic síndromes (MDS), TP53 mutations are associated with high-risk disease, rapid transformation to acute myeloid leukemia (AML)5, resistance to conventional therapies and dismal outcomes. Consistent with the tumor-suppressive role of TP53, patients harbor both mono- and biallelic mutations. However, the

IMPLICATIONS OF TP53 ALLELIC STATE FOR GENOME STABILITY, CLINICAL PRESENTATION AND OUTCOMES IN MYELODYSPLASTIC SYNDROMES Read More »